UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions

PloS one, 2013-03, Vol.8 (3), p.e57573-e57573

2013

Volltextzugriff (PDF)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286420982134-1756286420982134

2021

Volltextzugriff (PDF)

Best Practices for Intrathecal Baclofen Therapy: Troubleshooting

Neuromodulation (Malden, Mass.), 2016-08, Vol.19 (6), p.632-641

2016

Volltextzugriff (PDF)

Best Practices for Intrathecal Baclofen Therapy: Patient Selection

Neuromodulation (Malden, Mass.), 2016-08, Vol.19 (6), p.607-615

2016

Volltextzugriff (PDF)

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate

Drug design, development and therapy, 2014-01, Vol.8 (default), p.897-908

2014

Volltextzugriff (PDF)

Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management

Neuromodulation (Malden, Mass.), 2016-08, Vol.19 (6), p.623-631

2016

Volltextzugriff (PDF)

THUR 177 Efficacy of alemtuzumab retreatment after 2 initial courses

Journal of neurology, neurosurgery and psychiatry, 2018-10, Vol.89 (10), p.A23-A23

2018

Volltextzugriff (PDF)

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

Multiple sclerosis and related disorders, 2021-04, Vol.49, p.102717-102717, Article 102717

2021

Volltextzugriff (PDF)

Best Practices for Intrathecal Baclofen Therapy: Screening Test

Neuromodulation (Malden, Mass.), 2016-08, Vol.19 (6), p.616-622

2016

Volltextzugriff (PDF)

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Frontiers in neurology, 2019-03, Vol.10, p.253-253

2019

Volltextzugriff (PDF)

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab

JAMA neurology, 2013-03, Vol.70 (3), p.398

2013

Volltextzugriff (PDF)

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

Lancet neurology, 2008-02, Vol.7 (2), p.173-183

2008

Volltextzugriff (PDF)

Pediatric-Onset Multiple Sclerosis in African-American Black and European-Origin White Patients

Pediatric neurology, 2009, Vol.40 (1), p.31-33

2009

Volltextzugriff (PDF)

Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation‐Induced Neurodegeneration

Stem cells translational medicine, 2015-03, Vol.4 (3), p.252-260

2015

Volltextzugriff (PDF)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2011-09, Vol.4 (5), p.319-332

2011

Volltextzugriff (PDF)

Intracerebral haemorrhage during alemtuzumab administration

Lancet neurology, 2019-04, Vol.18 (4), p.329-331

2019

Volltextzugriff (PDF)

Poster 67 Best Practices in Intrathecal Baclofen Therapy: Dosing and Long-Term Management

PM & R, 2015-09, Vol.7 (9), p.S113-S114

2015

Volltextzugriff (PDF)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

Journal of neurology, neurosurgery and psychiatry, 2014-11, Vol.85 (11), p.1198-1208

2014

Volltextzugriff (PDF)

Multiple sclerosis: Five new things

Neurology. Clinical practice, 2013-10, Vol.3 (5), p.404-412

2013

Volltextzugriff (PDF)

Cases of COVID-19 in Alemtuzumab-Treated Patients With MS: Pharmacovigilance Report (2059)

Neurology, 2021-04, Vol.96 (15_supplement)

2021

Volltextzugriff (PDF)

Post Hoc Analysis of Nabiximols Efficacy by Concomitant Medication Use in 2 Enriched Placebo-Controlled Randomized Clinical Trials (RCTs) (P16-6.002)

Neurology, 2022-05, Vol.98 (18_supplement)

2022

Volltextzugriff (PDF)

Number Needed to Treat to Prevent Relapse and Disability Worsening Among Patients with Relapsing MS Treated with Teriflunomide or Cladribine (P3.2-074)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

Spontaneous Intracerebral Hemorrhage During Administration of Alemtuzumab for Multiple Sclerosis: A Case Series (S26.005)

Neurology, 2019-04, Vol.92 (15_supplement)

2019

Volltextzugriff (PDF)

AAN 2018 Treatment Guidelines: US Payers’ Perspective (803)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

1 – 25 von 76

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(74)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

Best Practices for Intrathecal Baclofen Therapy: Troubleshooting

Best Practices for Intrathecal Baclofen Therapy: Patient Selection

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate

Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management

THUR 177 Efficacy of alemtuzumab retreatment after 2 initial courses

Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years

Best Practices for Intrathecal Baclofen Therapy: Screening Test

Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab

Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician

Pediatric-Onset Multiple Sclerosis in African-American Black and European-Origin White Patients

Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation‐Induced Neurodegeneration

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

Intracerebral haemorrhage during alemtuzumab administration

Poster 67 Best Practices in Intrathecal Baclofen Therapy: Dosing and Long-Term Management

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

Multiple sclerosis: Five new things

Cases of COVID-19 in Alemtuzumab-Treated Patients With MS: Pharmacovigilance Report (2059)

Post Hoc Analysis of Nabiximols Efficacy by Concomitant Medication Use in 2 Enriched Placebo-Controlled Randomized Clinical Trials (RCTs) (P16-6.002)

Number Needed to Treat to Prevent Relapse and Disability Worsening Among Patients with Relapsing MS Treated with Teriflunomide or Cladribine (P3.2-074)

Spontaneous Intracerebral Hemorrhage During Administration of Alemtuzumab for Multiple Sclerosis: A Case Series (S26.005)

AAN 2018 Treatment Guidelines: US Payers’ Perspective (803)

Suchergebnisse filtern